Studies of golimumab yield positive results

06/12/2008 | Forbes

New findings are adding to evidence that golimumab, an injectable drug, holds promise as a treatment for rheumatoid arthritis when used in combination with methotrexate. One study found that 50-mg and 100-mg doses of golimumab caused disease remission in more than 30% of patients already on methotrexate, compared with 13% of those who received placebo and methotrexate. In another trial, 38% of patients who took golimumab and methotrexate experienced a 50% reduction in symptoms, while only 29% of those who got placebo plus methotrexate experienced similar improvement.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC